| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
| ln Vitro |
The paracellular permeability of immortalized airway epithelial cells is increased at a dose and time by polyinosinic-polycytidylic acid (0.5–5 μg/mL, 3–24 h) [4]. 16HBE14o- cells experience disruption of their epithelial apical junction complexes and tight junctions when exposed to polyinosinic-polycytidylic acid (5 μg/mL, 6 h) [4]. However, the acid does not cause any cytotoxicity to 16HBE14o- cells [4].
|
|---|---|
| ln Vivo |
Polyinosinic acid (2.5-10 mg/mL, stereotactic injection, single dosage) causes prolonged reactive reactions in the substantia nigra and dorsal striatum [2]. Polyinosinic-polycytidylic Acid (10 μg/mouse, i.p.) Polyinosinic-polycytidylic Acid (1.25 mg/kg, i.p., single dosage) boosts brain tumor lung growth via TLR3 and TLR4/MyD88 signaling in the MCAO model [3 ].
|
| Cell Assay |
Cell Cytotoxicity Assay[4]
Cell Types: 16HBE14o- Cell Tested Concentrations: 5 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: No significant accumulation of LDH in the cell culture medium |
| Animal Protocol |
Animal/Disease Models: lung tumor mice [3]
Doses: 10 μg/mouse Route of Administration: intraperitoneal (ip) injection Experimental Results: The growth of lung metastases in tumor-bearing mice was Dramatically diminished. . The number of lung lesions was diminished to approximately 40%. The number of BAL fluid cells increased Dramatically. Increased levels of INF-γ and IL-17A and diminished levels of IL-13. Increased TLR3 expression. Animal/Disease Models: Middle cerebral artery occlusion (MCAO) model mouse [5] Doses: 1.25 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Reduce focal brain I/R injury. Increase the expression of Bcl2, Hsp27 and Hsp70, reduce Bax expression, and reduce cell degeneration and apoptosis. Downregulating TLR4 signaling through TLR3 prevents cerebral ischemia and provides protection against cerebral I/R injury. |
| References |
[1]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.
[2]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101. [3]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364. [4]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11. [5]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794. [6]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [7]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. |
| Molecular Formula |
(C10H13N4O8P)X.(C9H14N3O8P)X
|
|---|---|
| Molecular Weight |
671.4025
|
| CAS # |
24939-03-5
|
| Related CAS # |
Poly (I:C):Kanamycin (1:1);Polyinosinic-polycytidylic acid potassium;31852-29-6;Polyinosinic-polycytidylic acid sodium;42424-50-0
|
| SMILES |
P(=O)(O[H])(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3C(N([H])C([H])=NC2=3)=O)O1)O[H])O[H].P(=O)(O[H])(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C(N=C(C([H])=C2[H])N([H])[H])=O)O1)O[H])O[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4894 mL | 7.4471 mL | 14.8943 mL | |
| 5 mM | 0.2979 mL | 1.4894 mL | 2.9789 mL | |
| 10 mM | 0.1489 mL | 0.7447 mL | 1.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
